FindTrial
Sign In

Precision dosing of imatinib and tamoxifen

Clinical Assessment of Pharmacometric model guided dosing in Oncology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/07/044424
Enrollment
180
Registered
2022-07-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50-C50- Malignant neoplasms of breast Health Condition 2: D72- Other disorders of white blood cells

Interventions

None listed

Sponsors

Manipal Academy of Higher Education
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with chronic myeloid leukemia and breast cancer

Exclusion criteria

Exclusion criteria: Patients taking concomitant cancer medication

Design outcomes

Primary

MeasureTime frame
Identification or development of generalizable pharmacometric model for imatinib and tamoxifen.Timepoint: At baseline—

Secondary

MeasureTime frame
Estimation of the impact of genetic variations and other potential covariates affecting imatinib and tamoxifen drug concentration in CML and breast cancer. Developing a dosing nomogram using the generalizable model for imatinib and tamoxifen to assist clinical decisions.Timepoint: At baseline, after 2year—

Countries

India

Contacts

Public ContactJaya Shree Dilli Batcha

Manipal college of pharmaceutical sciences

msv.rajan@manipal.edu9886921414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026